| 1 |
31853755 | A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions. | 2020 Jun |
2 |
| 2 |
31885304 | Quantitative evaluation of hepatic and intestinal induction of CYP3A in clinical practice. | 2020 Aug |
2 |
| 3 |
29926893 | CYP3A4 gene polymorphism is correlated with individual consumption of sufentanil. | 2018 Nov |
2 |
| 4 |
24671884 | A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. | 2014 Jul |
1 |
| 5 |
21562488 | Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction. | 2011 Jul |
3 |
| 6 |
19232844 | Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. | 2009 May 1 |
1 |
| 7 |
17554244 | Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. | 2007 Oct |
3 |
| 8 |
17112806 | Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. | 2006 Nov |
1 |
| 9 |
15557344 | Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes. | 2005 Mar |
10 |
| 10 |
15601808 | Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. | 2005 Jan |
4 |
| 11 |
15731592 | Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. | 2005 Mar |
5 |
| 12 |
16172184 | Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. | 2005 Oct |
3 |
| 13 |
16291719 | Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. | 2005 Dec |
5 |
| 14 |
12621385 | Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. | 2003 Mar |
8 |
| 15 |
12657846 | Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. | 2003 Apr |
1 |
| 16 |
11753266 | A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. | 2001 Dec |
7 |
| 17 |
10392320 | Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. | 1999 Jul |
1 |
| 18 |
9232131 | Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. | 1997 Jul |
1 |
| 19 |
9232132 | The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. | 1997 Jul |
2 |
| 20 |
9264313 | Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. | 1997 Jun 1 |
3 |
| 21 |
8712396 | Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. | 1996 Jan |
2 |
| 22 |
8968170 | Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. | 1996 Dec |
1 |
| 23 |
7995002 | Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. | 1994 Dec |
1 |
| 24 |
8484504 | Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance? | 1993 May |
2 |
| 25 |
1519785 | Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance. | 1992 Sep |
1 |